Kristan D. Guenterberg, M.D. (CV)


Post-Graduate Training:


  • M.S. in Medical Research 2007 – 2009 Columbus, OH
  • M.D., Loma Linda University School of Medicine 2001 – 2005 Loma Linda, CA
  • B.S. Walla Walla College 1997 – 2001 Walla Walla, WA Major: Health Science


  • 2005 – Alpha-Omega-Alpha, Medical School Honor Society
  • 2005 – David B Hinshaw, M.D. Award for outstanding academic achievement and clinical performance in surgery
  • 2005 – Loma Linda University Alumni Award in recognition of leadership in community service
  • 2009 – Best Resident Research Presentation 14th Annual Surgery Research Conference Department of Surgery, The Ohio State University May 22, 2009
  • 2009 – LT Furbrush Award for Cancer Research for dedication in the pursuit of difficult research topics
  • 2010 – Best Resident Research Presentation 15th Annual Surgery Research Conference Department of Surgery, The Ohio State University May 28, 2010


  • (2004 – 2005) Clinical Clerkship Directors Committee, LLU
  • (2005 – 2006) Department of Surgery Resident Review Committee, OSU
  • (2005 – 2008) Clinical Practice Guidelines Committee, OSU
  • (2006 – 2007) Trauma Quality Management Committee, OSU
  • (2009 – 2012) General Surgery Resident Curriculum Committee
  • (2013-2015) EPIC (Electronic Health Record) Implementation Committee
  • (2014-2016) Utilization Management Committee
  • (2015-2016) Hospital Design Committee
  • (2016-Present) Multi-Specialty Peer Review Committee

Professional Societies:

Personal Interests

  • Spending Time with Family
  • Travel
  • Reading
  • Hiking


  • Lesinski GB, Raig ET, Guenterberg KD, Brown L, Go MR, Shah NN, Lewis A, Quimper M, Hade E, Young G, Chaudhury AR, Ladner KJ, Guttridge DC, Bouchard P, Carson WE 3rd. “IFN-α and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis.” Cancer Research. 2008, 68 (20) 8351-60.
  • Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd. “A phase 1 trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.” Mol Cancer Ther. 2009, 8 (11) 2983-91.
  • Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, Young GS, Nuovo GJ, Mundy BL, Lesinski GB, Carson WE 3rd. “Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.” Mol Cancer Ther. 2010, 9 (2) 510-20.
  • Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, Chemudupati M, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE 3rd, Byrd JC, Tridandapani S. “Reciprocal regulation of activating and inhibitory Fc {gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.” Clin Cancer Res. 2010, 16 (7) 2065-75.
  • Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, Olencki TE, Carson WE 3rd. “A pilot study of Bevacizumab and Interferon-alpha2b in ocular melanoma.” Am J Clin Oncol. 2011, 34(1) 87-91.
  • Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rd. “Enhanced Anti-Tumor Activity of Interferon-Alpha in SOCS1-Deficient Mice is Mediated by CF4(+) and CD8 (+) T Cells.” Cancer Immunol Immunother. 2011, May 21. [Epub ahead of print]
  • Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, Carson WE 3rd. “Myeloid-derived Suppressor Cell Inhibition of the IFN Response in Tumor-bearing Mice.” Cancer Rs. 2011, 71(15) 5101-10.